Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00346268 |
The primary objective of this study is to demonstrate the opioid-sparing efficacy of parecoxib 40 mg intravenously given as a loading dose followed by 20 mg intravenously in the 24 hours after the end of surgery.
Condition | Intervention | Phase |
---|---|---|
Pain, Postoperative |
Drug: Morphine, placebo Drug: Morphine, parecoxib |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized, Double-Blind Study Of The Morphine-Sparing Efficacy And Safety Of Parecoxib Sodium 40 Mg IV Followed By 20 Mg IV Every 12 Hours In The Treatment Of Pain Following Radical Prostatectomy |
Estimated Enrollment: | 152 |
Study Start Date: | December 2006 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Morphine plus placebo: Active Comparator |
Drug: Morphine, placebo
Bolus plus PCA (Morphine: Patient controlled administration via pump PRN)
|
Morphine plus active drug: Active Comparator |
Drug: Morphine, parecoxib
Parecoxib, 40 mg loading dose IV plus 20 mg IV within 24 hours post surgery morphine bolus plus PCA
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
Germany | |
Pfizer Investigational Site | Recruiting |
Reutlingen, Germany, 72764 | |
Pfizer Investigational Site | Recruiting |
Essen, Germany, 45136 | |
Pfizer Investigational Site | Active, not recruiting |
Koeln-Lindenthal, Germany, 50925 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A3481066 |
Study First Received: | June 28, 2006 |
Last Updated: | December 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00346268 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Morphine Signs and Symptoms Parecoxib |
Postoperative Complications Pain Pain, Postoperative |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cyclooxygenase Inhibitors Central Nervous System Depressants Narcotics Enzyme Inhibitors Pharmacologic Actions Pathologic Processes |
Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents Analgesics, Opioid |